- Oops!Something went wrong.Please try again later.
NEW YORK, Sept. 19, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Silverback Therapeutics, Inc. ("Silverback" or the "Company") (NASDAQ: SBTX). Such investors are advised to contact Robert S. Willoughby at firstname.lastname@example.org or 888-476-6529, ext. 7980.
The investigation concerns whether Silverback and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
On or around December 3, 2020, Silverback conducted its initial public offering ("IPO"), offering 11.5 million shares of common stock priced at $21.00. Then, on September 13, 2021, Silverback issued a press release "announc[ing] that interim data from the dose-escalation portion of its Phase 1/1b clinical trial evaluating SBT6050 as a monotherapy and in combination with pembrolizumab in patients with advanced or metastatic HER2-expressing or amplified solid tumors will be presented at the upcoming European Society for Medical Oncology (ESMO) 2021 Congress from September 16-21, 2021" and advising that "[t]he accepted abstract . . . is now available on the ESMO website." Per the abstract, while there was a manageable safety profile for the Company's experimental therapy, the best overall response was PR (n=1), SD (n=3), and PD (n=10).
On this news, Silberback's stock price fell $4.54 per share, or 23.35%, to close at $14.90 per share on September 13, 2021.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Robert S. Willoughby
888-476-6529 ext. 7980
View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-silverback-therapeutics-inc---sbtx-301380066.html
SOURCE Pomerantz LLP